G
086060
vs
K
KOSPI 200
Over the past 12 months, GeneBioTech Co Ltd has underperformed KOSPI 200, delivering a return of +5% compared to KOSPI 200's +139% growth.
Stocks Performance
086060 vs KOSPI 200
Performance Gap
086060 vs KOSPI 200
Performance By Year
086060 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GeneBioTech Co Ltd
Glance View
GeneBioTech makes molecular diagnostic kits and lab reagents that detect diseases and genetic markers from patient samples. Its products are used mainly in hospitals, clinical laboratories, and other testing centers that need to identify infections or screen for specific DNA targets with PCR-based methods. The company earns money by selling test kits, reagents, and related consumables, and by supplying products to other diagnostic firms through OEM or contract manufacturing deals. In simple terms, it sits upstream in the healthcare chain: it does not treat patients itself, but sells the tools that labs use to run tests. What makes this business model different is that it depends on technical know-how in sample testing, assay design, and regulated diagnostics rather than on broad consumer sales. That gives GeneBioTech a focused role in the diagnostics market, where customers care most about accuracy, reliability, and compatibility with lab workflows.
